SS
CRSP icon

SBI Securities’s CRISPR Therapeutics CRSP Stock Holding History

SBI Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$399K Sell
7,314
-1,301
-15% -$68.6K 0.01% 482
2026
Q1 		$410K Sell
8,615
-291
-3% -$15.3K 0.01% 449
2025
Q4 		$467K Buy
8,906
+847
+11% +$50.7K 0.01% 411
2025
Q3 		$522K Buy
8,059
+321
+4% +$18.4K 0.01% 378
2025
Q2 		$376K Sell
7,738
-241
-3% -$9.33K 0.01% 426
2025
Q1 		$272K Buy
7,979
+849
+12% +$36K 0.01% 461
2024
Q4 		$281K Buy
+7,130
New +$337K 0.01% 456

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SBI Securities's CRSP Position: Q2 2026 in Review

SBI Securities reduced its CRISPR Therapeutics (CRSP) stake by 15% in Q2 2026, selling an estimated $68.6K and leaving 7,314 shares worth $399K. The position accounts for 0.01% of the portfolio, ranked #482.

SBI Securities first reported a position in CRSP in Q4 2024 and has held it in 7 quarters since. The position peaked at $522K in Q3 2025. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • SBI Securities held 7,314 shares of CRISPR Therapeutics worth $399K as of Q2 2026.
  • SBI Securities sold 1,301 CRISPR Therapeutics shares in Q2 2026, an estimated $68.6K.
  • CRISPR Therapeutics made up 0.01% of SBI Securities's portfolio in Q2 2026, its #482 holding.
  • SBI Securities first reported a position in CRISPR Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's CRISPR Therapeutics position peaked at $522K in Q3 2025.
  • 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.